Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  ISIS Pharmaceuticals, Inc.    ISIS

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

ISIS Pharmaceuticals, Inc. : Law Offices of Howard G. Smith Announces Class Action Lawsuit Against ISIS Pharmaceuticals, Inc.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/26/2013 | 08:35pm CEST

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed in the United States District Court for the Southern District of California on behalf of all purchasers of the common stock of ISIS Pharmaceuticals, Inc. ("ISIS" or the "Company") (NASDAQ:ISIS) between March 29, 2012 and October 15, 2012, inclusive (the "Class Period").

ISIS engages in the discovery and development of drugs utilizing antisense technology, primarily to treat cardiovascular, metabolic, severe and rare diseases, as well as cancer. The Complaint alleges that throughout the Class Period the Company and certain of its executive officers issued materially false and misleading statements regarding the safety and efficacy of the Company's flagship product, Kynamro (mipomersen sodium), for the treatment of patients with Homozygous Familial Hypercholesterolaemia. Specifically, the Complaint alleges that defendants, through a series of materially false and misleading statements regarding the safety and efficacy of the product, and reportedly positive results from Kynamro's clinical trials, conditioned investors to believe that Kynamro would receive approval from the U.S. Food and Drug Administration (FDA).

On October 16, 2012 the FDA published a clinical briefing document raising concerns regarding the safety and efficacy of Kynamro, noting among other things, abnormal growths or neoplasms developed in 3.1% of patients treated with Kynamro, as compared to only 0.9% of patients who took a placebo; that the data submitted by the Company was limited by a small sample size and a short treatment time, and that during the clinical testing two patients treated with Kynamro died of heart attacks and another patient died of acute liver failure. The FDA report concluded that this "imbalance in neoplasms will need to be assessed further in on-going and future studies and post-marketing (if approved)," and that "the potential for a contributing effect of mipomersen cannot be ruled out" in the patient deaths. As a result of these disclosures, ISIS shares declined nearly 22%, to close at $10.27 on October 16, 2012.

No class has yet been certified in this action. Until a class is certified, you are not represented by counsel unless you retain one. If you purchased ISIS common stock during the Class Period, you have certain rights, and have until February 26, 2013 to move for lead plaintiff status. To be a member of the class you need not take any action at this time, and you may retain counsel of your choice. If you wish to discuss this action or have any questions concerning this Notice or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, Toll Free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at http://www.howardsmithlaw.com.

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com


© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ISIS PHARMACEUTICALS, INC.
08/22 ISIS PHARMACEUTICALS : Ionis Pharmaceuticals' CEO, Dr. Stanley Crooke, Receives ..
08/18 IONIS PHARMACEUTICALS : Reports Financial Results and Highlights for Second Quar..
08/09 IONIS PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDIT..
08/09 IONIS PHARMACEUTICALS : reports 2Q loss
08/09 IONIS PHARMACEUTICALS INC : Results of Operations and Financial Condition, Finan..
08/09 IONIS PHARMACEUTICALS : Reports Financial Results and Highlights for Second Quar..
08/03 IONIS PHARMACEUTICALS INC : Other Events (form 8-K)
08/01 IONIS PHARMACEUTICALS : Leading The Biotechnology Sector Higher
08/01 IONIS PHARMACEUTICALS : Positive results halt Biogen, Ionis trial of SMA drug
08/01DJBIOGEN : Ionis Spinal Muscular Atrophy Therapy Meets Study Goal
More news
Sector news : Biotechnology & Medical Research - NEC
08/24DJAMGEN : FDA Rejects Amgen Hormonal-Imbalance Treatment
08/24DJAMGEN : FDA Rejects Amgen Hormonal-Imbalance Treatment
08/23DJDeal for Medivation Is the Latest In a Line of Similar Acquisitions -- WSJ
08/23DJPFIZER : to Acquire Key Drug -- WSJ
08/22DJPfizer's Medivation Deal Latest in Long Line of Similar Acquisitions
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
2015 Game Plan For The Week - Cramer's Mad Money (12/18/15)
2015 PREMARKET BIOTECH DIGEST : Portola's Milestone, Shkreli Resigns, BioMarin DMD Dr..
2015 Isis Pharma has had enough, name changed to Ionis Pharmaceuticals
2015 Bear Afoot? No Recession Needed For A Possible Sighting
2015 PREMARKET BIOTECH DIGEST : Gilead's Upside, Shire-Baxalta Deal, ARIAD Lowers Gui..
Advertisement
Financials ($)
Sales 2016 278 M
EBIT 2016 -87,3 M
Net income 2016 -99,4 M
Debt 2016 47,8 M
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales 2016 14,8x
EV / Sales 2017 13,1x
Capitalization 4 076 M
More Financials
Chart ISIS PHARMACEUTICALS, INC.
Duration : Period :
ISIS Pharmaceuticals, Inc. Technical Analysis Chart | ISIS | US4643301090 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus HOLD
Number of Analysts 13
Average target price 40,2 $
Spread / Average Target 19%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Stanley T. Crooke Chairman, President & Chief Executive Officer
B. Lynne Parshall Chief Operating Officer & Director
Elizabeth L. Hougen Chief Financial Officer & SVP-Finance
C. Frank Bennett Senior Vice President-Antisense Research
Joseph H. Wender Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ISIS PHARMACEUTICALS, ..-6.12%4 076
INCYTE CORPORATION-24.48%15 397
CELLTRION, INC.--.--%11 401
LONZA GROUP AG14.78%10 369
QUINTILES TRANSNATIONA..10.70%9 006
ALKERMES PLC-41.42%7 047
More Results